UK-based Achilles Therapeutics has announced the closing of its £100m Series B financing round, which was led by new investor RA Capital Management and founding investor Syncona.
3 September 2019 News
30 August 2019 News
ADCendo has secured a loan amount to advance its novel antibody-drug conjugates (ADCs) that are being developed to treat cancers.
29 August 2019 Comment
AstraZeneca and its partner, Merck & Co., have strengthened their position in ovarian cancer for their poly adenosine diphosphate (ADP) ribose polymerase (PARP) inhibitor. In aPhase III PAOLA-1, the therapy,...
29 August 2019 News
Roche has gained approval from the European Commission (EC) for Tecentriq (atezolizumab) with chemotherapy (Abraxane) to treat patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC).
28 August 2019 News
The European Commission has approved Bristol-Myers Squibb’s Empliciti (elotuzumab) plus pomalidomide and low-dose dexamethasone (EPd) to treat patients with refractory multiple myeloma.
27 August 2019 Comment
Between 2018 and 2028, cases of ovarian cancer are expected to increase at an Annual Growth Rate of 0.42% in each of the seven major markets (bar the US).
27 August 2019 News
The US Food and Drug Administration (FDA) has updated its draft recommendations regarding the inclusion of male patients with breast cancer in clinical trials.
23 August 2019 News
GlaxoSmithKline (GSK) has announced its experimental drug belantamab mafodotin (GSK2857916) has met its primary endpoint in the DREAMM-2 trial of patients with relapsed and refractory multiple myeloma.
22 August 2019 Comment
Imbruvica is facing increased competition from AstraZeneca’s second-generation BTK inhibitor, Calquence (acalabrutinib).